Q-omics provides the consensus-scored RNFT1-DT profile across patient tissues and cancer cell-line models. RNFT1-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNFT1-DT is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, RNFT1-DT RNA expression shows 16,387 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where RNFT1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNFT1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNFT1-DT survival associations across molecular data types. RNFT1-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNFT1-DT RNA expression–survival associations across cancer types. High RNFT1-DT expression shows unfavorable associations in SKCM, KICH and MESO, but favorable associations in KIRP, LUAD and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RNFT1-DT RNA expression.
This table summarizes RNFT1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNFT1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNFT1-DT shows lower tumor expression in HNSC, THCA, KIRC, KIRP, COAD and KICH. The HNSC box plot shows higher RNFT1-DT RNA expression in normal versus tumor tissue (log2 FC = −0.183, t-test p < 0.001).
This table shows molecular features associated with RNFT1-DT in patient tissues and cancer cell lines. In patient samples, RNFT1-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
